Safety and efficacy of oral antiplatelet for patients who had acute ischaemic stroke undergoing endovascular therapy

作     者：Xiaochuan Huo Raynald Jing Jing Anxin Wang Dapeng Mo Feng Gao Ning Ma Yilong Wang Yongjun Wang Zhongrong Miao 

作者机构：Neurointervention centerBeijing Tiantan HospitalCapital Medical UniversityBeijingChina Department of NeurologyBeijing Tiantan HospitalCapital Medical UniversityBeijingChina China National Clinical Research Center for Neurological DiseasesBeijingChina Center of StrokeBeijing Institute for Brain DisordersBeijingChina Beijing Tiantan HospitalBeijingChina Neurointervention centerBeijing Tiantan HospitalBeijingChina 

出 版 物：《Stroke & Vascular Neurology》 (卒中与血管神经病学（英文）)

年 卷 期：2021年第6卷第2期

页      面：230-237页

核心收录：

学科分类：1002[医学-临床医学] 100204[医学-神经病学] 10[医学] 

基　　金：Study funded by the National Key Research and Development Program of China grant number 2016YFC1301500 

主　　题：mortality patients acute 

摘      要：Background and purpose To investigate the safety and efficacy of oral antiplatelet therapy(APT)for patients who had acute ischaemic stroke(AIS),receiving endovascular therapy(EVT).Methods Patients were divided into non-APT group and APT(single APT or dual APT(DAPT)*** safety and efficacy endpoints at 3-month follow-up were symptomatic intracranial haemorrhage(sICH),recanalisation rate,clinical outcome and *** Among 915 patients who had AIS,those in APT group(n=199)showed shorter puncture-to recanalisation time,lower frequency of intravenous thrombolysis and more use of tirofiban compared with those in non-antiplatelet group(n=716)(p0.05 for all).Oral APT was found to be associated with superior clinical outcome compared with non-APT(APT(44.2%)versus non-APT(41.1%)),adjusted OR=2.605,95% CI 1.244 to 5.455,p=0.011).DAPT showed superior clinical outcome compared with non-APT(DAPT(56.5%)versus non-APT(41.1%),adjusted OR=5.405,95% CI 1.614 to 18.102,p=0.006)and lower risk of mortality at 3-month follow-up(DAPT(4.8%)versus non-DAPT(17.7%),adjusted OR=0.008,95%CI 0.000 to 0.441,p=0.019).There was no significant difference in sICH between the two *** Oral APT prior to undergoing EVT is safe and may accompany with superior clinical *** may associate with superior clinical outcomes and lower risk of mortality.